Sebastian M, Eberhardt WEE, Hoffknecht P., et al. - This study examined a large, representative, real-world cohort from Germany to assess the outcome with standard treatment in patients with G12C mutated non-small cell lung cancer (NSCLC). Between December 2015 and June 2019, a total of 1,039 patients with advanced KRAS-mutant or -wild-type NSCLC without druggable alterations were recruited in the prospective, observational registry CRISP by 98 centers in Germany. They examined details on treatment, best response, and outcome for patients with KRAS wildtype, G12C, and non-G12C mutations. There were 160 (15.4%) patients within the study population who presented with KRAS G12C, 251 (24.2%) with non-G12C mutations, 628 (60.4%) with KRAS wildtype. High PD-L1 expression (tumor proportion score, TPS > 50%) was documented for 28.0%, 43.5%, and 28.9% (wildtype, G12C, non-G12C) of the tested patients; 68.8%, 89.3%, and 87.7% of the patients received first-line treatment combined with an immune checkpoint-inhibitor in 2019. In a multivariate Cox model, TPS > 50% vs TPS < 1% was linked with a significantly lower risk of mortality. There were no differences in clinical outcome between KRAS wildtype, G12C or non-G12C mutations and KRAS mutational status was not prognostic in the model.